Clinical Trial

Asciminib in HER2+ Breast Cancer Brain Metastases

Name: Asciminib in HER2+ Breast Cancer Brain Metastases — clinical trial record (NCT07136428)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASCENdANT

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-23

Trial Details

NCT Number	NCT07136428
Lead Sponsor	Duke University Collaborators: Novartis
Conditions	HER2+ Metastatic Breast Cancer
Enrollment	42 participants
Start Date	2026-07-07
Primary Completion	2030-11-01 (estimated)
Study Completion	2032-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-22